Search

Author/Creator Logan, Theodore F.

1. A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma. Issue 1 (27th July 2018)

Authors:
Clark, Joseph I.; Singh, Jatinder; Ernstoff, Marc S.; Lao, Christopher D.; Flaherty, Lawrence E.; Logan, Theodore F.; Curti, Brendan; Agarwala, Sanjiv S.; Taback, Bret; Cranmer, Lee; Lutzky, Jose; Luna, Theresa L.; Aung, Sandra; Lawson, David H.
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 6:Issue 1(2018)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma. Issue 14 (5th April 2019)

Authors:
Voss, Martin H.; Bhatt, Rupal S.; Vogelzang, Nicholas J.; Fishman, Mayer; Alter, Robert S.; Rini, Brian I.; Beck, J. Thaddeus; Joshi, Monika; Hauke, Ralph; Atkins, Michael B.; Burgess, Earle; Logan, Theodore F.; Shaffer, David; Parikh, Rahul; Moazzam, Nauman; Zhang, Xiaosha; Glasser, Chad; Sherma...
Journal:
Cancer
Issue:
Volume 125:Issue 14(2019)
Page Start:
2400
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134. Issue 2 (27th September 2022)

Authors:
Atkins, Michael B.; Lee, Sandra J.; Chmielowski, Bartosz; Tarhini, Ahmad A.; Cohen, Gary I.; Truong, Thach-Giao; Moon, Helen H.; Davar, Diwakar; O'Rourke, Mark; Stephenson, Joseph J.; Curti, Brendan D.; Urba, Walter J.; Brell, Joanna M.; Funchain, Pauline; Kendra, Kari L.; Ikeguchi, Alexandra P.;...
Journal:
Journal of clinical oncology
Issue:
Volume 41:Issue 2(2023)
Page Start:
186
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. Issue 1 (19th December 2017)

Authors:
Curti, Brendan; Daniels, Gregory A.; McDermott, David F.; Clark, Joseph I.; Kaufman, Howard L.; Logan, Theodore F.; Singh, Jatinder; Kaur, Meenu; Luna, Theresa L.; Gregory, Nancy; Morse, Michael A.; Wong, Michael K. K.; Dutcher, Janice P.
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 5:Issue 1(2017)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. NCI 8628: A randomized phase 2 study of ziv‐aflibercept and high‐dose interleukin 2 or high‐dose interleukin 2 alone for inoperable stage III or IV melanoma. Issue 22 (10th October 2018)

Authors:
Tarhini, Ahmad A.; Frankel, Paul; Ruel, Christopher; Ernstoff, Marc S.; Kuzel, Timothy M.; Logan, Theodore F.; Khushalani, Nikhil I.; Tawbi, Hussein A.; Margolin, Kim A.; Awasthi, Sanjay; Butterfield, Lisa H.; McDermott, David; Chen, Alice; Lara, Primo N.; Kirkwood, John M.
Journal:
Cancer
Issue:
Volume 124:Issue 22(2018)
Page Start:
4332
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗